Paradigm Biopharmaceuticals

Paradigm Biopharma (PAR) listed on the ASX in August 2015. Our focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. We are leading research and development to bring new orthopaedic and respiratory applications to market. PPS PPS is an FDA approved drug that has a long track record of treating inflammation, having been used narrowly to treat bladder inflammation (interstitial cystitis) and for preventing DVT. Our major clinical applications currently under investigation are: - Orthopaedic – Bone Marrow Edema and Osteoarthritis - Arthritogenic alphaviruses – Ross River Fever and Chikungunya - Chronic Obstructive Pulmonary Disease - Respiratory – Allergic Rhinitis and Asthma A smart approach By working closely with the proprietary manufacturer of PPS, we are able to leverage substantial knowledge and expertise available from earlier regulatory filings. This involves decades of accumulated toxicology safety data, formulation know how, and extensive published information about PPS’s mode of action, which primarily involves modulation of proteins impacting inflammation. With this foundation, Paradigm Biopharma minimises its risk profile, and is able to accelerate the drug development cycle at significantly reduced costs. About us We have a focused, multidisciplinary management team with broad fundamental experience of complex diseases and networked pathways, and special emphasis on inflammation and regenerative medicine. We also have deep knowledge of taking drugs through clinical trials and structuring partnerships with small and large corporations. We have built and sustained strong and successful collaborations with the leading clinical researchers in the field, and continue to develop partnerships with high quality European manufacturers.